[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619328":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fabrice BERNA, MD, PhD","CONTACT","33 3 88 11 64 62","fabrice.berna@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Service de Psychiatrie 1 - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France",{"type":22,"coordinates":23},"Point",[24,25],7.74553,48.58392,{"lat":25,"lon":24},[28,29,31,33],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":30,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":32,"role":30,"phone":7,"phoneExt":7,"email":7},"Matthias BRUNN, MD",{"name":34,"role":30,"phone":7,"phoneExt":7,"email":7},"Maeva MUSSO, MD",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619328",false,"NCT07343193","Deprescribing Antipsychotics: a Multiple Case Study","DEPRESC","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients with a psychotic or related disorder\n* Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025\n\nExclusion Criteria:\n\n\\- Patients who have expressed their opposition to participating in the study","ALL","18 Years",{"count":46,"type":47},30,"ESTIMATED","OBSERVATIONAL","The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.\n\nThe fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.\n\nThis argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.",[51],"Psychotic Disorder",[51,53,54],"Psychotic or Related Disorder","Antipsychotics","2026-01-06",{"date":57,"type":58},"2026-01-15","ACTUAL",{"date":60,"type":58},"2025-09-09",{"date":62,"type":47},"2026-09-09",{"name":5,"class":6},1]